Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT ID: NCT00002744
Last Updated: 2017-02-09
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
1970 participants
Study Classification
INTERVENTIONAL
Study Start Date
1996-05-31
Study Completion Date
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia
PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
NCT00002812
Leukemia
COMPLETED
PHASE3
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005585
Leukemia
COMPLETED
PHASE3
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00002816
Leukemia
COMPLETED
PHASE3
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
NCT00003671
Leukemia
COMPLETED
PHASE2
Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
NCT00002785
Leukemia
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OBJECTIVES: I. Identify response related factors predictive of relapse among children with previously untreated standard risk acute lymphoblastic leukemia (ALL). II. Determine the prognostic significance of residual leukemic blasts at specific times during induction therapy: M3 marrow status (greater than 25% blasts) at day 7; M2 status (5%-25% blasts) at day 14; and residual circulating leukemic blasts at days 7 and 14. III. Determine the prognostic significance of residual leukemic burden, as measured by fluorescence activated cell sorting/leukemic progenitor cell assay, on marrow aspirates acquired at the end of induction therapy, at the beginning of maintenance therapy, and at the completion of all therapy in patients with B precursor ALL. IV. Determine the prognostic significance of residual t(1;19) detected in marrow aspirates by PCR-based analyses of the fusion transcript E2A-PBX1 at the end of induction therapy, at the beginning of maintenance therapy, and at the completion of all therapy. V. Examine the interrelationships among these response-related prognostic factors and their correlation with ploidy, karyotype, and immunophenotype. VI. Determine, in a randomized study, whether substitution of oral thioguanine (TG) for oral mercaptopurine (MP) during consolidation, interim maintenance, and maintenance therapy improves event-free survival for patients with standard-risk ALL. VII. Study and compare the cellular pharmacokinetics of oral MP and oral TG during interim maintenance and maintenance therapy in selected patients. VIII. Compare the concentrations of MP and TG red blood cell metabolites (i.e., nucleotides, nucleosides, free bases, and methylated metabolites) during interim maintenance and maintenance therapy, and determine whether low levels of metabolites predict relapse in selected patients. IX. Determine the activities of thiopurine methyltransferase and hypoxanthine guanine phosphoribosyl transferase several times during interim maintenance and maintenance treatment, and compare the activities between the two thiopurine treatment groups in selected patients. X. Compare the incidence of central nervous system (CNS) relapse and event-free survival in patients receiving intrathecal methotrexate (MTX) vs. triple intrathecal chemotherapy (MTX/cytarabine/hydrocortisone) for presymptomatic CNS treatment. XI. Determine whether cerebrospinal fluid (CSF) terminal deoxynucleotidyl transferase (TdT) positivity predicts for CNS or marrow relapse by measuring TdT activity on CSF cytospins in cases with low white blood cell count (less than 5 cells per cubic millimeter) and suspected or questionable "blasts" during maintenance therapy. XII. Determine event-free survival in patients with standard-risk ALL and M3 marrow at day 14 when treated with intensive therapy designed for higher-risk ALL.
OUTLINE: This is a randomized study. Patients are stratified according to participating institution. The following acronyms are used: ARA-C Cytarabine, NSC-63878 ASP Asparaginase (E. coli), NSC-109229 CTX Cyclophosphamide, NSC-26271 DM Dexamethasone, NSC-34521 DNR Daunorubicin, NSC-82151 DOX Doxorubicin, NSC-123127 HC Hydrocortisone, NSC-10483 MP Mercaptopurine, NSC-755 MTX Methotrexate, NSC-740 PEG-ASP Pegaspargase, NSC-624239 PRED Prednisone, NSC-10023 TG Thioguanine, NSC-752 TIT Triple Intrathecal Therapy (IT MTX/IT ARA-C/IT HC) VCR Vincristine, NSC-67574 Induction: All patients receive oral PRED on days 0-27, VCR IV on days 0, 7, 14, and 21, and ASP IM 3 times a week for 3 weeks beginning on day 2-4. ARA-C IT is administered on day 0, and MTX IT is administered on days 7 and 28 (days 7, 14, 21, and 28 if CNS disease at diagnosis). Following Induction, patients who achieve remission are randomly assigned to 1 of 4 treatment arms. Arm I: Consolidation (begins day 28 of Induction): PRED is tapered from Induction over 10 days. Patients receive VCR IV on day 0, oral MP on days 1-27, and MTX IT on days 7, 14, and 21 (only day 7 if CNS disease at diagnosis). Interim Maintenance 1 (begins day 28 of Consolidation): Patients receive oral PRED on days 0-4 and 28-32, VCR IV days 0 and 28, oral MTX on days 0, 7, 14, 21, 28, 35, 42, and 49, and oral MP on days 0-49. Delayed Intensification 1 (begins day 56 of Interim Maintenance 1): Patients receive oral DM on days 0-6 and 14-20, VCR IV on days 0, 7, and 14, DOX IV over 15-120 min on days 0, 7, and 14, ASP IM twice a week for 2 weeks beginning day 2-4, CTX IV over 20-30 min on day 28, oral TG on days 28-41, ARA-C IV or SC on days 29-32 and 36-39, and MTX IT on days 0, 28, and 35. Interim Maintenance 2 (begins day 56 of Delayed Intensification 1): Patients receive PRED/VCR/MTX/MP as in Interim Maintenance 1. Delayed Intensification 2 (begins day 56 of Interim Maintenance 2): Patients receive DM/VCR/DOX/ASP, CTX/TG/ARA-C, and MTX IT as in Delayed Intensification 1. Maintenance (begins day 56 of Delayed Intensification 2): Patients receive oral PRED on days 0-4, 28-32, and 56-60, VCR IV on days 0, 28, and 56, oral MP on days 0-83, oral MTX on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77 (omitted during wk of IT therapy), and MTX IT on day 0. Treatment continues every 84 days for 2 years (girls) or 3 years (boys) from the beginning of Interim Maintenance 1. Arm II: Patients receive treatment as in arm I, except TIT is TIT substituted for MTX IT. Arm III: Patients receive treatment as in arm I with oral TG substituted for oral MTX in Consolidation, Interim Maintenance 1 and 2, and Maintenance. If secondary veno-occlusive disease occurs, MP is substituted for TG during Maintenance. Arm IV: Patients receive treatment as in arm III with TIT substituted for MTX IT. If secondary veno-occlusive disease occurs, MP is substituted for TG during Maintenance. Patients with M3 marrow after 2 weeks or M2 marrow after 4 weeks of Induction, or with Philadelphia chromosome (t\[9;22\]\[q34;q11\]), t(4;11)(q21;q23), or hypodiploidy, proceed to the following more intensive treatment regimen for further therapy: Induction (begins day 14 to day 19 of initial Induction): Patients receive oral PRED on days 14-27, VCR IV on days 14 and 21 (day 14 dose omitted if day 14 dose from original Induction already given), DNR IV continuously on days 14-16 (48 hours total), ASP IM three times a week for 9 total doses (including those received on original Induction), MTX IT on days 28 and 35 (days 21, 28, and 35 if CNS disease at diagnosis). Patients with M1/M2 bone marrow after day 35 proceed to Consolidation. Consolidation (begins day 28 or 35 of Induction in this regimen, depending on timing of entry on this regimen): PRED is tapered from Induction over 10 days. Patients receive CTX IV 20-30 minutes on days 0 and 28, oral MP on days 0-13 and 28-41, ARA-C IV or SC on days 1-4, 8-11, 29-32, and 36-39, VCR IV on days 14, 21, 42, and 49, PEG-ASP IM on days 14 and 42, and MTX IT on days 7, 14, and 21 (only day 7 if CNS disease at diagnosis). Patients with M1 or M2 marrow and no extramedullary leukemia after day 63 proceed to Interim Maintenance 1. Interim Maintenance 1 (begins day 63 of Consolidation): Patients receive VCR IV on days 0, 10, 20, 30, and 40, MTX IV on days 0, 10, 20, 30, and 40, and PEG-ASP IM on days 1 and 21. Patients with M1 bone marrow after day 56 proceed to Delayed Intensification I. Delayed Intensification 1 (begins day 56 of Interim Maintenance 1): Patients receive oral DM on days 0-6 and 14-20, VCR IV on days 0, 7, 14, 42, and 49, DOX IV over 15-120 minutes on days 0, 7, and 14, PEG-ASP IM on days 3 and 42, CTX IV over 20-30 minutes on day 28, oral TG on days 28-41, ARA-C IV or SC on days 29-32 and 36-39, and MTX IT on days 28 and 35. Interim Maintenance 2 (begins day 56 of Delayed Intensification 1): Patients receive VCR/MTX/PEG-ASP as in Interim Maintenance 1, and MTX IT on days 0, 20, and 40. Delayed Intensification 2 (begins day 56 of Interim Maintenance 2): Patients receive DM/VCR/DOX/PEG-ASP, CTX/TG/ARA-C, and MTX IT as in Delayed Intensification 1. Maintenance (begins day 56 of Delayed Intensification 2): Patients receive PRED/VCR/MP/MTX, and MTX IT as in arm I Maintenance. Patients with CNS or testicular involvement at diagnosis receive appropriate radiotherapy concurrent with Consolidation. Radiotherapy begins within 4 days of initiation of Consolidation. Craniospinal irradiation is given 5 days a week. Testicular irradiation is given to both testes 5 days a week over 2-3 weeks. Patients are followed every 6-8 weeks during year 1, every 3 months during year 2, every 6 months during year 3, and then annually thereafter.
PROJECTED ACCRUAL: A total of 1970 patients will be accrued for this study within 3.5 years.
OUTLINE: This is a randomized study. Patients are stratified according to participating institution. The following acronyms are used: ARA-C Cytarabine, NSC-63878 ASP Asparaginase (E. coli), NSC-109229 CTX Cyclophosphamide, NSC-26271 DM Dexamethasone, NSC-34521 DNR Daunorubicin, NSC-82151 DOX Doxorubicin, NSC-123127 HC Hydrocortisone, NSC-10483 MP Mercaptopurine, NSC-755 MTX Methotrexate, NSC-740 PEG-ASP Pegaspargase, NSC-624239 PRED Prednisone, NSC-10023 TG Thioguanine, NSC-752 TIT Triple Intrathecal Therapy (IT MTX/IT ARA-C/IT HC) VCR Vincristine, NSC-67574 Induction: All patients receive oral PRED on days 0-27, VCR IV on days 0, 7, 14, and 21, and ASP IM 3 times a week for 3 weeks beginning on day 2-4. ARA-C IT is administered on day 0, and MTX IT is administered on days 7 and 28 (days 7, 14, 21, and 28 if CNS disease at diagnosis). Following Induction, patients who achieve remission are randomly assigned to 1 of 4 treatment arms. Arm I: Consolidation (begins day 28 of Induction): PRED is tapered from Induction over 10 days. Patients receive VCR IV on day 0, oral MP on days 1-27, and MTX IT on days 7, 14, and 21 (only day 7 if CNS disease at diagnosis). Interim Maintenance 1 (begins day 28 of Consolidation): Patients receive oral PRED on days 0-4 and 28-32, VCR IV days 0 and 28, oral MTX on days 0, 7, 14, 21, 28, 35, 42, and 49, and oral MP on days 0-49. Delayed Intensification 1 (begins day 56 of Interim Maintenance 1): Patients receive oral DM on days 0-6 and 14-20, VCR IV on days 0, 7, and 14, DOX IV over 15-120 min on days 0, 7, and 14, ASP IM twice a week for 2 weeks beginning day 2-4, CTX IV over 20-30 min on day 28, oral TG on days 28-41, ARA-C IV or SC on days 29-32 and 36-39, and MTX IT on days 0, 28, and 35. Interim Maintenance 2 (begins day 56 of Delayed Intensification 1): Patients receive PRED/VCR/MTX/MP as in Interim Maintenance 1. Delayed Intensification 2 (begins day 56 of Interim Maintenance 2): Patients receive DM/VCR/DOX/ASP, CTX/TG/ARA-C, and MTX IT as in Delayed Intensification 1. Maintenance (begins day 56 of Delayed Intensification 2): Patients receive oral PRED on days 0-4, 28-32, and 56-60, VCR IV on days 0, 28, and 56, oral MP on days 0-83, oral MTX on days 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77 (omitted during wk of IT therapy), and MTX IT on day 0. Treatment continues every 84 days for 2 years (girls) or 3 years (boys) from the beginning of Interim Maintenance 1. Arm II: Patients receive treatment as in arm I, except TIT is TIT substituted for MTX IT. Arm III: Patients receive treatment as in arm I with oral TG substituted for oral MTX in Consolidation, Interim Maintenance 1 and 2, and Maintenance. If secondary veno-occlusive disease occurs, MP is substituted for TG during Maintenance. Arm IV: Patients receive treatment as in arm III with TIT substituted for MTX IT. If secondary veno-occlusive disease occurs, MP is substituted for TG during Maintenance. Patients with M3 marrow after 2 weeks or M2 marrow after 4 weeks of Induction, or with Philadelphia chromosome (t\[9;22\]\[q34;q11\]), t(4;11)(q21;q23), or hypodiploidy, proceed to the following more intensive treatment regimen for further therapy: Induction (begins day 14 to day 19 of initial Induction): Patients receive oral PRED on days 14-27, VCR IV on days 14 and 21 (day 14 dose omitted if day 14 dose from original Induction already given), DNR IV continuously on days 14-16 (48 hours total), ASP IM three times a week for 9 total doses (including those received on original Induction), MTX IT on days 28 and 35 (days 21, 28, and 35 if CNS disease at diagnosis). Patients with M1/M2 bone marrow after day 35 proceed to Consolidation. Consolidation (begins day 28 or 35 of Induction in this regimen, depending on timing of entry on this regimen): PRED is tapered from Induction over 10 days. Patients receive CTX IV 20-30 minutes on days 0 and 28, oral MP on days 0-13 and 28-41, ARA-C IV or SC on days 1-4, 8-11, 29-32, and 36-39, VCR IV on days 14, 21, 42, and 49, PEG-ASP IM on days 14 and 42, and MTX IT on days 7, 14, and 21 (only day 7 if CNS disease at diagnosis). Patients with M1 or M2 marrow and no extramedullary leukemia after day 63 proceed to Interim Maintenance 1. Interim Maintenance 1 (begins day 63 of Consolidation): Patients receive VCR IV on days 0, 10, 20, 30, and 40, MTX IV on days 0, 10, 20, 30, and 40, and PEG-ASP IM on days 1 and 21. Patients with M1 bone marrow after day 56 proceed to Delayed Intensification I. Delayed Intensification 1 (begins day 56 of Interim Maintenance 1): Patients receive oral DM on days 0-6 and 14-20, VCR IV on days 0, 7, 14, 42, and 49, DOX IV over 15-120 minutes on days 0, 7, and 14, PEG-ASP IM on days 3 and 42, CTX IV over 20-30 minutes on day 28, oral TG on days 28-41, ARA-C IV or SC on days 29-32 and 36-39, and MTX IT on days 28 and 35. Interim Maintenance 2 (begins day 56 of Delayed Intensification 1): Patients receive VCR/MTX/PEG-ASP as in Interim Maintenance 1, and MTX IT on days 0, 20, and 40. Delayed Intensification 2 (begins day 56 of Interim Maintenance 2): Patients receive DM/VCR/DOX/PEG-ASP, CTX/TG/ARA-C, and MTX IT as in Delayed Intensification 1. Maintenance (begins day 56 of Delayed Intensification 2): Patients receive PRED/VCR/MP/MTX, and MTX IT as in arm I Maintenance. Patients with CNS or testicular involvement at diagnosis receive appropriate radiotherapy concurrent with Consolidation. Radiotherapy begins within 4 days of initiation of Consolidation. Craniospinal irradiation is given 5 days a week. Testicular irradiation is given to both testes 5 days a week over 2-3 weeks. Patients are followed every 6-8 weeks during year 1, every 3 months during year 2, every 6 months during year 3, and then annually thereafter.
PROJECTED ACCRUAL: A total of 1970 patients will be accrued for this study within 3.5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Leukemia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Therapy defined in description.
Group Type
EXPERIMENTAL
asparaginase
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cytarabine
Intervention Type
DRUG
daunorubicin hydrochloride
Intervention Type
DRUG
dexamethasone
Intervention Type
DRUG
doxorubicin hydrochloride
Intervention Type
DRUG
mercaptopurine
Intervention Type
DRUG
methotrexate
Intervention Type
DRUG
pegaspargase
Intervention Type
DRUG
prednisone
Intervention Type
DRUG
therapeutic hydrocortisone
Intervention Type
DRUG
thioguanine
Intervention Type
DRUG
vincristine sulfate
Intervention Type
DRUG
low-LET cobalt-60 gamma ray therapy
Intervention Type
RADIATION
low-LET photon therapy
Intervention Type
RADIATION
Arm 2
Therapy defined in description.
Group Type
EXPERIMENTAL
asparaginase
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cytarabine
Intervention Type
DRUG
daunorubicin hydrochloride
Intervention Type
DRUG
dexamethasone
Intervention Type
DRUG
doxorubicin hydrochloride
Intervention Type
DRUG
mercaptopurine
Intervention Type
DRUG
methotrexate
Intervention Type
DRUG
pegaspargase
Intervention Type
DRUG
prednisone
Intervention Type
DRUG
therapeutic hydrocortisone
Intervention Type
DRUG
thioguanine
Intervention Type
DRUG
vincristine sulfate
Intervention Type
DRUG
low-LET cobalt-60 gamma ray therapy
Intervention Type
RADIATION
low-LET photon therapy
Intervention Type
RADIATION
Arm 3
Therapy defined in description.
Group Type
EXPERIMENTAL
asparaginase
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cytarabine
Intervention Type
DRUG
daunorubicin hydrochloride
Intervention Type
DRUG
dexamethasone
Intervention Type
DRUG
doxorubicin hydrochloride
Intervention Type
DRUG
mercaptopurine
Intervention Type
DRUG
methotrexate
Intervention Type
DRUG
pegaspargase
Intervention Type
DRUG
prednisone
Intervention Type
DRUG
therapeutic hydrocortisone
Intervention Type
DRUG
thioguanine
Intervention Type
DRUG
vincristine sulfate
Intervention Type
DRUG
low-LET cobalt-60 gamma ray therapy
Intervention Type
RADIATION
low-LET photon therapy
Intervention Type
RADIATION
Arm 4
Therapy defined in description.
Group Type
EXPERIMENTAL
asparaginase
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cytarabine
Intervention Type
DRUG
daunorubicin hydrochloride
Intervention Type
DRUG
dexamethasone
Intervention Type
DRUG
doxorubicin hydrochloride
Intervention Type
DRUG
mercaptopurine
Intervention Type
DRUG
methotrexate
Intervention Type
DRUG
pegaspargase
Intervention Type
DRUG
prednisone
Intervention Type
DRUG
therapeutic hydrocortisone
Intervention Type
DRUG
thioguanine
Intervention Type
DRUG
vincristine sulfate
Intervention Type
DRUG
low-LET cobalt-60 gamma ray therapy
Intervention Type
RADIATION
low-LET photon therapy
Intervention Type
RADIATION
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
asparaginase
Intervention Type
DRUG
cyclophosphamide
Intervention Type
DRUG
cytarabine
Intervention Type
DRUG
daunorubicin hydrochloride
Intervention Type
DRUG
dexamethasone
Intervention Type
DRUG
doxorubicin hydrochloride
Intervention Type
DRUG
mercaptopurine
Intervention Type
DRUG
methotrexate
Intervention Type
DRUG
pegaspargase
Intervention Type
DRUG
prednisone
Intervention Type
DRUG
therapeutic hydrocortisone
Intervention Type
DRUG
thioguanine
Intervention Type
DRUG
vincristine sulfate
Intervention Type
DRUG
low-LET cobalt-60 gamma ray therapy
Intervention Type
RADIATION
low-LET photon therapy
Intervention Type
RADIATION
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
L-Asparaginase - Erwinia
NSC-106977
Cytoxan
NSC-26271.
Cytosine Arabinoside
Ara-C
Cytosar-U
NSC-82151
Decadron
NSC-34521
Adriamycin
NSC-123127
6-MP
Purinethol
NSC-740
PEG Asparaginase
Oncaspar®
NSC-10023
6-TG
NSC-752
Oncovin
NSC-67574
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
DISEASE CHARACTERISTICS: Newly diagnosed acute lymphoblastic leukemia (ALL) obtained by bone marrow aspirate or bone marrow biopsy No greater than 25% L3 blasts Initial white blood cell count less than 50,000/mm3 (performed at CCG institution) Massive lymphadenopathy, massive splenomegaly, and/or large mediastinal mass allowed CNS or testicular leukemia allowed Allogeneic bone marrow transplant should be considered (if donor available) for patients with Philadelphia chromosome (t\[9;22\]\[q34;q11\]) or translocation (4;11)(q21;q23)
PATIENT CHARACTERISTICS: Age: 1 through 9 Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not specified
PRIOR CONCURRENT THERAPY: No prior treatment for ALL Biologic therapy: Not specified Chemotherapy: Intrathecal cytarabine (IT ARA-C) may begin prior to registration provided systemic chemotherapy initiated within 72 hours after IT ARA-C Endocrine therapy: See Radiotherapy At least 1 month since prior systemic steroids Steroids given for less than 48 hours allowed Inhaled corticosteroids allowed at any time Radiotherapy: Radiotherapy or dexamethasone for mediastinal mass causing superior mediastinal syndrome allowed prior to registration, if indicated Surgery: Not specified
PATIENT CHARACTERISTICS: Age: 1 through 9 Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not specified
PRIOR CONCURRENT THERAPY: No prior treatment for ALL Biologic therapy: Not specified Chemotherapy: Intrathecal cytarabine (IT ARA-C) may begin prior to registration provided systemic chemotherapy initiated within 72 hours after IT ARA-C Endocrine therapy: See Radiotherapy At least 1 month since prior systemic steroids Steroids given for less than 48 hours allowed Inhaled corticosteroids allowed at any time Radiotherapy: Radiotherapy or dexamethasone for mediastinal mass causing superior mediastinal syndrome allowed prior to registration, if indicated Surgery: Not specified
Minimum Eligible Age
1 Year
Maximum Eligible Age
9 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Children's Oncology Group
NETWORK
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Linda C. Stork, MD
Role: STUDY_CHAIR
Doernbecher Children's Hospital at Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Long Beach Memorial Medical Center
Long Beach, California, United States
Site Status
Children's Hospital Los Angeles
Los Angeles, California, United States
Site Status
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States
Site Status
Children's Hospital of Orange County
Orange, California, United States
Site Status
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, United States
Site Status
Children's Hospital of Denver
Denver, Colorado, United States
Site Status
Children's National Medical Center
Washington D.C., District of Columbia, United States
Site Status
University of Chicago Cancer Research Center
Chicago, Illinois, United States
Site Status
Indiana University Cancer Center
Indianapolis, Indiana, United States
Site Status
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Site Status
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site Status
University of Minnesota Cancer Center
Minneapolis, Minnesota, United States
Site Status
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Site Status
Children's Mercy Hospital - Kansas City
Kansas City, Missouri, United States
Site Status
University of Nebraska Medical Center
Omaha, Nebraska, United States
Site Status
Kaplan Cancer Center
New York, New York, United States
Site Status
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site Status
Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Site Status
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, United States
Site Status
Children's Hospital Medical Center - Cincinnati
Cincinnati, Ohio, United States
Site Status
Ireland Cancer Center
Cleveland, Ohio, United States
Site Status
Children's Hospital of Columbus
Columbus, Ohio, United States
Site Status
Doernbecher Children's Hospital
Portland, Oregon, United States
Site Status
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site Status
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site Status
Vanderbilt Cancer Center
Nashville, Tennessee, United States
Site Status
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Site Status
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Site Status
Children's Hospital and Medical Center - Seattle
Seattle, Washington, United States
Site Status
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site Status
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, United States
Site Status
Princess Margaret Hospital for Children
Perth, Western Australia, Australia
Site Status
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Site Status
IWK Grace Health Centre
Halifax, Nova Scotia, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Australia
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, Winick NJ, Hunger SP, Gaynon PS, Loh ML; Children's Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia. 2008 Dec;22(12):2142-50. doi: 10.1038/leu.2008.251. Epub 2008 Sep 25.
Reference Type
BACKGROUND
Matloub Y, Asselin BL, Stork LC, et al.: Outcome of children with T-Cell acute lymphoblastic leukemia (T-ALL) and standard risk (SR) features: results of CCG-1952, CCG-1991 and POG 9404. [Abstract] Blood 104 (11): A-680, 195a, 2004.
Reference Type
BACKGROUND
Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, Hutchinson R, Heerema NA, Sorrell AD, Masterson M, Bleyer A, Gaynon PS. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 2010 Apr 8;115(14):2740-8. doi: 10.1182/blood-2009-07-230656. Epub 2010 Feb 1.
Reference Type
RESULT
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2009 Dec 10;27(35):5986-92. doi: 10.1200/JCO.2009.23.5408. Epub 2009 Nov 2.
Reference Type
RESULT
Malempati S, Gaynon PS, Sather H, La MK, Stork LC; Children's Oncology Group. Outcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children's Oncology Group study CCG-1952. J Clin Oncol. 2007 Dec 20;25(36):5800-7. doi: 10.1200/JCO.2007.10.7508.
Reference Type
RESULT
Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC; Children's Oncology Group. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood. 2006 Aug 15;108(4):1165-73. doi: 10.1182/blood-2005-12-011809. Epub 2006 Apr 11.
Reference Type
RESULT
Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005 Jan;44(1):21-8. doi: 10.1002/pbc.20193.
Reference Type
RESULT
Malempati S, Gaynon PS, Sather H, et al.: Outcome after relapse among children with standard risk (SR) ALL treated on CCG-1952. [Abstract] Blood 104 (11): A-520, 2004.
Reference Type
RESULT
Stork LC, Sather H, Hutchinson RJ, et al.: Comparison of mercaptopurine (MP) with thioguanine (TG) and IT methotrexate (ITM) with IT "triples" (ITT) in children with SR-ALL: results of CCG-1952. [Abstract] Blood 100 (11 Pt 1): A-585, 156a, 2002.
Reference Type
RESULT
Stork LC, Sather H, Yanofsky R, et al.: Hyperdiploidy with trisomy 10 and TEL-AML1 expression among children with standard risk acute lymphoblastic leukemia (SR-ALL): a CCG-1952 report. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1476, 2001.
Reference Type
RESULT
Gaynon PS, Stork L, Sather H, et al.: Leukemic progenitor cell content of pre- and post-induction chemotherapy bone marrow specimens from children with newly diagnosed or relapsed acute lymphoblastic leukemia (ALL). [Abstract] Proceedings of the American Society of Clinical Oncology 18: A-2187, 567a, 1999.
Reference Type
RESULT
Stork LC, Erdmann G, Adamson P, et al.: Oral 6-thioguanine causes relatively mild and reversible hepatic veno-occlusive disease(VOD). J Pediatr Hematol Oncol 20: 400a, 1998.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCG-1952
Identifier Type: -
Identifier Source: secondary_id
CDR0000064665
Identifier Type: OTHER
Identifier Source: secondary_id
1952
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT00613457
COMPLETED
PHASE3
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
NCT00004228
COMPLETED
PHASE3
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
NCT00022737
COMPLETED
PHASE3
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00003217
COMPLETED
PHASE1
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
NCT00003728
UNKNOWN
PHASE3
Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia
NCT00002704
COMPLETED
PHASE2
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT00003423
UNKNOWN
PHASE3
Treatment of Acute Lymphoblastic Leukemia in Children
NCT00165178
COMPLETED
PHASE3
Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
NCT00015873
COMPLETED
PHASE3
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
NCT01117441
COMPLETED
PHASE3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03020030
ACTIVE_NOT_RECRUITING
PHASE3
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00049569
COMPLETED
NA
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00002756
COMPLETED
PHASE2
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NCT00003273
WITHDRAWN
PHASE2
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
NCT00003650
COMPLETED
PHASE3
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
NCT00866307
COMPLETED
PHASE1
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT00186875
COMPLETED
PHASE2
Combination Chemotherapy in Treating Children With Lymphoma
NCT00002590
COMPLETED
PHASE2
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children
NCT06099366
RECRUITING
PHASE2
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
NCT00550992
UNKNOWN
NA
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
NCT00096135
COMPLETED
NA
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
NCT00019409
WITHDRAWN
PHASE3
Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma
NCT00002691
COMPLETED
PHASE2
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
NCT01403415
COMPLETED
PHASE1
Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma
NCT00002618
COMPLETED
PHASE3